Ras/Raf/MEK/ERK通路靶点药物联合治疗新进展

被引：34

作者：

孟丽君

姜藻

机构：

[1] 东南大学临床医学院附属中大医院肿瘤科

来源：

肿瘤 | 2009年 / 29卷 / 01期

关键词：

ras蛋白质类; raf激酶类; 丝裂原激活蛋白激酶激酶类; 细胞外信号调节MAP激酶类; 药物疗法,联合;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 [肿瘤学];

摘要：

Ras/Raf/MEK/ERK通路的异常与肿瘤的发生密切相关,由于其导致细胞增殖失控和凋亡受阻,因此可作为肿瘤治疗的一个靶点。目前在研究各靶点单药疗效的同时,更多的研究侧重于将对应Ras/Raf/MEK/ERK通路各靶点的药物与一般的放化疗、其他靶点药物和内分泌治疗等联合应用,并且取得了一定的进展。

引用

页码：97 / 100

页数：4

共 8 条

[1]

MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth [J].

Takayama, Yuichi ;

Kokuryo, Toshio ;

Yokoyama, Yukihiro ;

Nagino, Masato ;

Nimura, Yuji ;

Senga, Takeshi ;

Hamaguchi, Michinari .

CANCER LETTERS, 2008, 264 (02) :241-249

[2]

Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma [J].

Huether, Alexander ;

Hoepfner, Michael ;

Baradari, Viola ;

Schuppan, Detlef ;

Scheruebl, Hans .

BIOCHEMICAL PHARMACOLOGY, 2007, 73 (09) :1308-1317

[3]

Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme [J].

Moyal, Elizabeth Cohen-Jonathan ;

Laprie, Anne ;

Delannes, Martine ;

Poublanc, Muriel ;

Catalaa, Isabelle ;

Dalenc, Florence ;

Berchery, Delphine ;

Sabatier, Jean ;

Bousquet, Philippe ;

De Porre, Peter ;

Alaux, Beatrice ;

Toulas, Christine .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (05) :1396-1401

[4]

MEK1/2 inhibition promotes Taxotere? lethality in mammary tumors in vivo.[J].Adly Yacoub;Donna Gilfor;William Hawkins;Margaret A. Park;David Hanna;Michael P. Hagan;David T. Curiel;Paul B. Fisher;Steven Grant;Paul Dent.Cancer Biology & Therapy.2006, 10

[5]

New strategies based on zoledronic acid/tipifarnib combination in the therapy of prostate cancer [J].

Caraglia, M ;

Marra, M ;

Leonetti, C ;

Meo, G ;

Bruzzese, F ;

Addeo, S ;

Zupi, G ;

Abbruzzese, A ;

Budillon, A .

BONE, 2006, 38 (03) :S44-S44

[6]

Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma [J].

Carter, Christopher A. ;

Chen, Charles ;

Brink, Cheryl ;

Vincent, Patrick ;

Maxuitenko, Yulia Y. ;

Gilbert, Karen S. ;

Waud, William R. ;

Zhang, Xiaomei .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (02) :183-195

[7]

Comparison of strategies targeting Raf-1 mRNA in ovarian cancer [J].

Mullen, P ;

McPhillips, F ;

Monia, BP ;

Smyth, JF ;

Langdon, SP .

INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (06) :1565-1571

[8]

Phase trial of sorafenib plus interferon alfa-2b as first-or second-line therapy in patients with metastatic renal cell cancer..Gollob JA;Rathmell WK;Richmond TM;.J Clin Oncol.2007, 22

← 1 →